Baxalta Inc (BXLT) : Spark Investment Management scooped up 229,800 additional shares in Baxalta Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 12, 2016. The investment management firm now holds a total of 274,500 shares of Baxalta Inc which is valued at $11.6 Million.Baxalta Inc makes up approximately 1.19% of Spark Investment Management’s portfolio.
Other Hedge Funds, Including , Thrivent Financial For Lutherans reduced its stake in BXLT by selling 1,112,135 shares or 98.23% in the most recent quarter. The Hedge Fund company now holds 20,091 shares of BXLT which is valued at $851,657.Tradewinds Global Investors reduced its stake in BXLT by selling 716,033 shares or 81.27% in the most recent quarter. The Hedge Fund company now holds 165,000 shares of BXLT which is valued at $7 Million. Baxalta Inc makes up approx 0.43% of Tradewinds Global Investors’s portfolio. Cannell Peter B Co Inc sold out all of its stake in BXLT during the most recent quarter. The investment firm sold 27,040 shares of BXLT which is valued $1.1 Million.Investment House reduced its stake in BXLT by selling 1,050 shares or 1.9% in the most recent quarter. The Hedge Fund company now holds 54,179 shares of BXLT which is valued at $2.2 Million. Baxalta Inc makes up approx 0.36% of Investment House’s portfolio.Wedbush Securities Inc boosted its stake in BXLT in the latest quarter, The investment management firm added 140 additional shares and now holds a total of 5,447 shares of Baxalta Inc which is valued at $224,253. Baxalta Inc makes up approx 0.04% of Wedbush Securities Inc’s portfolio.
Baxalta Inc opened for trading at $44.21 and hit $44.65 on the upside on Friday, eventually ending the session at $44.43, with a gain of 1.62% or 0.71 points. The heightened volatility saw the trading volume jump to 1,35,80,226 shares. Company has a market cap of $30,369,682 M.
On the company’s financial health, Baxalta Inc reported $0.47 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $0.46. The company had revenue of $1548.00 million for the quarter, compared to analysts expectations of $1474.42 million. The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.40 EPS.
Investors should note that on May 10, 2016, Baxalta Inc announced a cash dividend of $0.0700. The company’s management has announced Jun 8, 2016 as the ex-dividend date and fixed the record date on Jun 10, 2016. The payable date has been fixed on Jul 1, 2016.
Baxalta Incorporated is a biopharmaceutical company. The Company develops manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute medical conditions. The Company also focuses on disease areas including oncology as well as technology platforms including gene therapy and biosimilars. The Company has a portfolio of various therapies that address unmet medical needs across various disease areas including hemophilia immunology and oncology. The Company’s products include ADVATE RECOMBINATE HEMOFIL M Immunate Immunine PROTHROMPLEX TOTAL RIXUBIS FACTOR VII NF BEBULIN FEIBA OBIZUR GAMMAGARD LIQUID GAMMAGARD S/D Subcuvia HYQVIA FLEXBUMIN BUMINATE ARALAST NP GLASSIA NP CEPROTIN and ANTITHROMBIN III IMMUNO.